Skip to main content
Top
Published in: Thrombosis Journal 1/2023

Open Access 01-12-2023 | Thymoma | Case Report

A case-report of the unprovoked thrombotic event in a patient with thymoma and severe FVII deficiency

Authors: Lei Li, Xi Wu, Wenman Wu, Qiulan Ding, Xuefeng Wang

Published in: Thrombosis Journal | Issue 1/2023

Login to get access

Abstract

Background

Factor VII deficiency is a rare bleeding disorder caused by a deficiency of clotting factor VII. However, there have been some case reports of venous thrombosis in patients with factor VII deficiency, especially underlying the prothrombotic risk factors exposure. Patients with factor VII deficiency require special considerations before undergoing surgery to minimize the risk of bleeding or thrombogenesis.

Case presentation

Here, we described a patient with early-stage thymoma and severe factor VII deficiency who experienced an unprovoked thrombotic episode before thymectomy and a fatal thrombotic event after surgery. By adopting gene screening, a reported homozygous F7 mutation (p.His408Gln) and a novel heterozygous PROS1 mutation (p.Pro147Ala) were identified. The former resulted in severe factor VII deficiency but did not protect against thrombosis, and the latter was correlated with normal expression and cofactor activities of protein S through the thrombin generation test. The perioperative infusion of recombinant factor VII concentrate and the absence of antithrombotic prophylaxis may collectively contribute to her fatal thrombotic event after surgery.

Conclusions

For the patients with severe factor VII deficiency undergoing surgery, uniform replacement therapy may not be recommended, and antithrombotic prophylaxis should be used in the case with thrombotic history to minimize the risk of bleeding and thrombogenesis.
Literature
1.
go back to reference Wang KL, Chu PH, Lee CH, Pai PY, Lin PY, Shyu KG, et al. Management of venous thromboembolisms: part I. The Consensus for deep vein thrombosis. Acta Cardiol Sin. 2016;32:1–22.PubMedPubMedCentral Wang KL, Chu PH, Lee CH, Pai PY, Lin PY, Shyu KG, et al. Management of venous thromboembolisms: part I. The Consensus for deep vein thrombosis. Acta Cardiol Sin. 2016;32:1–22.PubMedPubMedCentral
2.
go back to reference Stevens SM, Woller SC, Bauer KA, Kasthuri R, Cushman M, Streiff M, et al. Guidance for the evaluation and treatment of hereditary and acquired thrombophilia. J Thromb Thrombolysis. 2016;41:154–64.CrossRefPubMedPubMedCentral Stevens SM, Woller SC, Bauer KA, Kasthuri R, Cushman M, Streiff M, et al. Guidance for the evaluation and treatment of hereditary and acquired thrombophilia. J Thromb Thrombolysis. 2016;41:154–64.CrossRefPubMedPubMedCentral
3.
go back to reference Girolami A, Ruzzon E, Tezza F, Scandellari R, Vettore S, Girolami B. Arterial and venous thrombosis in rare congenital bleeding disorders: a critical review. Haemophilia. 2006;12:345–51.CrossRefPubMed Girolami A, Ruzzon E, Tezza F, Scandellari R, Vettore S, Girolami B. Arterial and venous thrombosis in rare congenital bleeding disorders: a critical review. Haemophilia. 2006;12:345–51.CrossRefPubMed
4.
go back to reference Ruiz-Saez A. Occurrence of thrombosis in rare bleeding disorders. Semin Thromb Hemost. 2013;39:684–92.CrossRefPubMed Ruiz-Saez A. Occurrence of thrombosis in rare bleeding disorders. Semin Thromb Hemost. 2013;39:684–92.CrossRefPubMed
5.
go back to reference Girolami A, Peroni E, Girolami B, Ferrari S, Lombardi AM. Congenital factor XI and factor VII deficiencies assure an apparent opposite protection against arterial or venous thrombosis: an intriguing observation. Hematology. 2016;21:486–9.CrossRefPubMed Girolami A, Peroni E, Girolami B, Ferrari S, Lombardi AM. Congenital factor XI and factor VII deficiencies assure an apparent opposite protection against arterial or venous thrombosis: an intriguing observation. Hematology. 2016;21:486–9.CrossRefPubMed
6.
go back to reference Mariani G, Herrmann FH, Schulman S, Batorova A, Wulff K, Etro D, et al. Thrombosis in inherited factor VII deficiency. J Thromb Haemost. 2003;1:2153–8.CrossRefPubMed Mariani G, Herrmann FH, Schulman S, Batorova A, Wulff K, Etro D, et al. Thrombosis in inherited factor VII deficiency. J Thromb Haemost. 2003;1:2153–8.CrossRefPubMed
7.
go back to reference Marty S, Barro C, Chatelain B, Fimbel B, Tribout B, Reynaud J, et al. The paradoxical association between inherited factor VII deficiency and venous thrombosis. Haemophilia. 2008;14:564–70.CrossRefPubMed Marty S, Barro C, Chatelain B, Fimbel B, Tribout B, Reynaud J, et al. The paradoxical association between inherited factor VII deficiency and venous thrombosis. Haemophilia. 2008;14:564–70.CrossRefPubMed
8.
go back to reference Girolami A, Tezza F, Scandellari R, Vettore S, Girolami B. Associated prothrombotic conditions are probably responsible for the occurrence of thrombosis in almost all patients with congenital FVII deficiency. Critical review of the literature. J Thromb Thrombolysis. 2010;30:172–8.CrossRefPubMed Girolami A, Tezza F, Scandellari R, Vettore S, Girolami B. Associated prothrombotic conditions are probably responsible for the occurrence of thrombosis in almost all patients with congenital FVII deficiency. Critical review of the literature. J Thromb Thrombolysis. 2010;30:172–8.CrossRefPubMed
9.
go back to reference Masaoka A, Monden Y, Nakahara K, Tanioka T. Follow-up study of thymomas with special reference to their clinical stages. Cancer. 1981;48:2485–92.CrossRefPubMed Masaoka A, Monden Y, Nakahara K, Tanioka T. Follow-up study of thymomas with special reference to their clinical stages. Cancer. 1981;48:2485–92.CrossRefPubMed
10.
go back to reference Koga K, Matsuno Y, Noguchi M, Mukai K, Asamura H, Goya T, et al. A review of 79 thymomas: modification of staging system and reappraisal of conventional division into invasive and non-invasive thymoma. Pathol Int. 1994;44:359–67.CrossRefPubMed Koga K, Matsuno Y, Noguchi M, Mukai K, Asamura H, Goya T, et al. A review of 79 thymomas: modification of staging system and reappraisal of conventional division into invasive and non-invasive thymoma. Pathol Int. 1994;44:359–67.CrossRefPubMed
11.
go back to reference Rosai J, Sobin LH. Histological typing of tumors of the thymus.2nd edition.World Health Organization International Histological Classification of Tunmors. Springer-Verlag 1999: 1–65. Rosai J, Sobin LH. Histological typing of tumors of the thymus.2nd edition.World Health Organization International Histological Classification of Tunmors. Springer-Verlag 1999: 1–65.
12.
go back to reference Ding Q, Shen W, Ye X, Wu Y, Wang X, Wang H. Clinical and genetic features of protein C deficiency in 23 unrelated chinese patients. Blood Cells Mol Dis. 2013;50:53–8.CrossRefPubMed Ding Q, Shen W, Ye X, Wu Y, Wang X, Wang H. Clinical and genetic features of protein C deficiency in 23 unrelated chinese patients. Blood Cells Mol Dis. 2013;50:53–8.CrossRefPubMed
13.
go back to reference Li L, Wu X, Wu W, Ding Q, Cai X, Wang X. Clinical manifestation and mutation spectrum of 53 unrelated pedigrees with Protein S Deficiency in China. Thromb Haemost; 2019. Li L, Wu X, Wu W, Ding Q, Cai X, Wang X. Clinical manifestation and mutation spectrum of 53 unrelated pedigrees with Protein S Deficiency in China. Thromb Haemost; 2019.
14.
go back to reference Castoldi E, Maurissen LF, Tormene D, Spiezia L, Gavasso S, Radu C, et al. Similar hypercoagulable state and thrombosis risk in type I and type III protein S-deficient individuals from families with mixed type I/III protein S deficiency. Haematologica. 2010;95:1563–71.CrossRefPubMedPubMedCentral Castoldi E, Maurissen LF, Tormene D, Spiezia L, Gavasso S, Radu C, et al. Similar hypercoagulable state and thrombosis risk in type I and type III protein S-deficient individuals from families with mixed type I/III protein S deficiency. Haematologica. 2010;95:1563–71.CrossRefPubMedPubMedCentral
15.
go back to reference Maurissen LF, Castoldi E, Simioni P, Rosing J, Hackeng TM. Thrombin generation-based assays to measure the activity of the TFPI-protein S pathway in plasma from normal and protein S-deficient individuals. J Thromb Haemost. 2010;8:750–8.CrossRefPubMed Maurissen LF, Castoldi E, Simioni P, Rosing J, Hackeng TM. Thrombin generation-based assays to measure the activity of the TFPI-protein S pathway in plasma from normal and protein S-deficient individuals. J Thromb Haemost. 2010;8:750–8.CrossRefPubMed
16.
go back to reference Lou C, Jiang J, Chen W, Zhang Z, Xu G, Liu Y et al. Structural and functional characterization of novel F7 mutations identified in Chinese factor VII-deficient patients. 2023. Lou C, Jiang J, Chen W, Zhang Z, Xu G, Liu Y et al. Structural and functional characterization of novel F7 mutations identified in Chinese factor VII-deficient patients. 2023.
17.
go back to reference Bui H, Helms JL, Sierra-Hoffman M, Stevens ML, Deliz-Aguirre R, Castro-Lainez MT, et al. Thymoma causing bilateral Upper Extremity Deep vein thrombosis. Respir Med Case Rep. 2020;30:101049.PubMedPubMedCentral Bui H, Helms JL, Sierra-Hoffman M, Stevens ML, Deliz-Aguirre R, Castro-Lainez MT, et al. Thymoma causing bilateral Upper Extremity Deep vein thrombosis. Respir Med Case Rep. 2020;30:101049.PubMedPubMedCentral
18.
go back to reference Ball SL, Cocks HC. Thymoma complicated by deep vein thrombosis of the arm. BMJ Case Rep 2015;2015. Ball SL, Cocks HC. Thymoma complicated by deep vein thrombosis of the arm. BMJ Case Rep 2015;2015.
19.
go back to reference Scorsetti M, Leo F, Trama A, D’Angelillo R, Serpico D, Macerelli M, et al. Thymoma and thymic carcinomas. Crit Rev Oncol Hematol. 2016;99:332–50.CrossRefPubMed Scorsetti M, Leo F, Trama A, D’Angelillo R, Serpico D, Macerelli M, et al. Thymoma and thymic carcinomas. Crit Rev Oncol Hematol. 2016;99:332–50.CrossRefPubMed
21.
go back to reference Girolami A, de Marinis GB, Bonamigo E, Lombardi AM. Recombinant FVIIa concentrate-associated thrombotic events in congenital bleeding disorders other than hemophilias. Hematology. 2012;17:346–9.CrossRefPubMed Girolami A, de Marinis GB, Bonamigo E, Lombardi AM. Recombinant FVIIa concentrate-associated thrombotic events in congenital bleeding disorders other than hemophilias. Hematology. 2012;17:346–9.CrossRefPubMed
22.
go back to reference Giansily-Blaizot M, Marty S, Chen SW, Pellequer JL, Schved JF. Is the coexistence of thromboembolic events and factor VII deficiency fortuitous? Thromb Res. 2012;130(Suppl 1):47–9.CrossRef Giansily-Blaizot M, Marty S, Chen SW, Pellequer JL, Schved JF. Is the coexistence of thromboembolic events and factor VII deficiency fortuitous? Thromb Res. 2012;130(Suppl 1):47–9.CrossRef
23.
go back to reference Fernandes N, Mosnier LO, Tonnu L, Heeb MJ. Zn(2)(+) -containing protein S inhibits extrinsic factor X-activating complex independently of tissue factor pathway inhibitor. J Thromb Haemost. 2010;8:1976–85.CrossRefPubMedPubMedCentral Fernandes N, Mosnier LO, Tonnu L, Heeb MJ. Zn(2)(+) -containing protein S inhibits extrinsic factor X-activating complex independently of tissue factor pathway inhibitor. J Thromb Haemost. 2010;8:1976–85.CrossRefPubMedPubMedCentral
24.
go back to reference Alshaikh NA, Rosing J, Thomassen M, Castoldi E, Simioni P, Hackeng TM. New functional assays to selectively quantify the activated protein C- and tissue factor pathway inhibitor-cofactor activities of protein S in plasma. J Thromb Haemost. 2017;15:950–60.CrossRefPubMed Alshaikh NA, Rosing J, Thomassen M, Castoldi E, Simioni P, Hackeng TM. New functional assays to selectively quantify the activated protein C- and tissue factor pathway inhibitor-cofactor activities of protein S in plasma. J Thromb Haemost. 2017;15:950–60.CrossRefPubMed
Metadata
Title
A case-report of the unprovoked thrombotic event in a patient with thymoma and severe FVII deficiency
Authors
Lei Li
Xi Wu
Wenman Wu
Qiulan Ding
Xuefeng Wang
Publication date
01-12-2023
Publisher
BioMed Central
Published in
Thrombosis Journal / Issue 1/2023
Electronic ISSN: 1477-9560
DOI
https://doi.org/10.1186/s12959-023-00494-3

Other articles of this Issue 1/2023

Thrombosis Journal 1/2023 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine